Preventive and therapeutic role of dietary inositol supplementation in periconceptional period and during pregnancy: A summary of evidences and future applications

Reproductive Sciences

Volumn 23, Issue 3, 2016, Pages 278-288

  Noventa, Marco ^a   Vitagliano, Amerigo ^a   Quaranta, Michela ^b   Borgato, Shara ^a   Abdulrahim, Baydaa ^c   Gizzo, Salvatore ^a,c  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c NORTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

dietary inositol supplementation; folate resistant neural tube defects.; gestational diabetes; periconceptional period; pregnancy; preventive and therapeutic role

Indexed keywords

INOSITOL; FOLIC ACID; VITAMIN B COMPLEX;

CONCEPTION; DIET SUPPLEMENTATION; EMBRYO DEVELOPMENT; FOLATE RESISTANT EMBRYO NEURAL TUBE DEFECT; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NEURAL TUBE DEFECT; NONHUMAN; PREGNANCY; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; ANIMAL; DIETARY SUPPLEMENT; FEMALE; METABOLISM; NEURAL TUBE DEFECTS; PREPREGNANCY CARE; PROCEDURES;

ANIMALS; DIETARY SUPPLEMENTS; FEMALE; FOLIC ACID; HUMANS; INOSITOL; NEURAL TUBE DEFECTS; PRECONCEPTION CARE; PREGNANCY; VITAMIN B COMPLEX;

EID: 84957951485     PISSN: 19337191     EISSN: 19337205     Source Type: Journal    
DOI: 10.1177/1933719115594018     Document Type: Review

References (56)

1. Cetin I, Berti C, Calabrese S,. Role of micronutrients in the periconceptional period. Hum Reprod Update. 2010; 16 (1): 80-95.
2. Sinclair KD, Allegrucci C, Singh R, et al. DNA methylation, insulin resistance, and blood pressure in offspring determined by maternal periconceptional B vitamin and methionine status. Proc Natl Acad Sci USA. 2007; 104 (49): 19351-19356.
3. Junien C,. Impact of diets and nutrients/drugs on early epigenetic programming. J Inherit Metab Dis. 2006; 29 (2-3): 359-365.
4. Gizzo S, Patrelli TS, Rossanese M, et al. An update on diabetic women obstetrical outcomes linked to preconception and pregnancy glycemic profile: a systematic literature review. ScientificWorldJournal. 2013; 2013: 254901.
5. Smith BJ, Cinnadaio N, Cheung NW, Bauman A, Tapsell LC, van der Ploeg HP,. Investigation of a lifestyle change strategy for high-risk women with a history of gestational diabetes. Diabetes Res Clin Pract. 2014; 106 (3): e60-e63.
6. Hui AL, Back L, Ludwig S, et al. Effects of lifestyle intervention on dietary intake, physical activity level, and gestational weight gain in pregnant women with different pre-pregnancy Body Mass Index in a randomized control trial. BMC Pregnancy Childbirth. 2014; 14: 331.
7. Facchinetti F, Dante G, Petrella E, Neri I,. Dietary interventions, lifestyle changes, and dietary supplements in preventing gestational diabetes mellitus: a literature review. Obstet Gynecol Surv. 2014; 69 (11): 669-680.
8. Vitagliano A, Noventa M, Gizzo S,. Is it time to consider patients suffering from endometriosis-related infertility as "novel candidates" for targeted peri-conceptional D-chiro inositol supplementation? Hypothesis, rationale and some considerations. J Assist Reprod Genet. 2015; 32 (3): 407-408.
9. Colazingari S, Treglia M, Najjar R, Bevilacqua A,. The combined therapy myo-inositol plus D-chiro-inositol, rather than D-chiro-inositol, is able to improve IVF outcomes: results from a randomized controlled trial. Arch Gynecol Obstet. 2013; 288 (6): 1405-1411.
10. Lisi F, Carfagna P, Oliva MM, et al. Pretreatment with myo-inositol in non polycystic ovary syndrome patients undergoing multiple follicular stimulation for IVF: a pilot study. Reprod Biol Endocrinol. 2012; 10: 52.
11. Bizzarri M, Carlomagno G,. Inositol: history of an effective therapy for polycystic ovary syndrome. Eur Rev Med Pharmacol Sci. 2014; 18 (13): 1896-1903.
12. Croze ML, Soulage CO,. Potential role and therapeutic interests of myo-inositol in metabolic diseases. Biochimie. 2013; 95 (10): 1811-1827.
13. Laganà AS, Barbaro L, Pizzo A,. Evaluation of ovarian function and metabolic factors in women affected by polycystic ovary syndrome after treatment with D-Chiro-Inositol. Arch Gynecol Obstet. 2015; 291 (5): 1181-1186.
14. Malvasi A, Casciaro F, Minervini MM, et al. Myo-inositol, D-chiro-inositol, folic acid and manganese in second trimester of pregnancy: a preliminary investigation. Eur Rev Med Pharmacol Sci. 2014; 18 (2): 270-274.
15. Larner J, Brautigan DL, Thorner MO,. D-chiro-inositol glycans in insulin signaling and insulin resistance. Mol Med. 2010; 16 (11-12): 543-552.
16. Unfer V, Porcaro G,. Updates on the myo-inositol plus D-chiro-inositol combined therapy in polycystic ovary syndrome. Expert Rev Clin Pharmacol. 2014; 7 (5): 623-631.
17. Larner J,. D-chiro-inositol - its functional role in insulin action and its deficit in insulin resistance. Int J Exp Diabetes Res. 2002; 3 (1): 47-60.
18. Wilson MP, Hugge C, Bielinska M, Nicholas P, Majerus PW, Wilson DB,. Neural tube defects in mice with reduced levels of inositol 1,3,4-trisphosphate 5/6-kinase. Proc Natl Acad Sci USA. 2009; 106 (24): 9831-9835.
19. Khandelwal M, Reece EA, Wu YK, Borenstein M,. Dietary myo-inositol therapy in hyperglycemia-induced embryopathy. Teratology. 1998; 57 (2): 79-84.
20. Scioscia M, Gumaa K, Selvaggi LE, Rodeck CH, Rademacher TW,. Increased inositol phosphoglycan P-type in the second trimester in pregnant women with type 2 and gestational diabetes mellitus. J Perinat Med. 2009; 37 (5): 469-471.
21. Baker L, Piddington R, Goldman A, Egler J, Moehring J,. Myo-inositol and prostaglandins reverse the glucose inhibition of neural tube fusion in cultured mouse embryos. Diabetologia. 1990; 33 (10): 593-596.
22. Hashimoto M, Akazawa S, Akazawa M, et al. Effects of hyperglycaemia on sorbitol and myo-inositol contents of cultured embryos: treatment with aldose reductase inhibitor and myo-inositol supplementation. Diabetologia. 1990; 33 (10): 597-602.
23. Akashi M, Akazawa S, Akazawa M, et al. Effects of insulin and myo-inositol on embryo growth and development during early organogenesis in streptozocin-induced diabetic rats. Diabetes. 1991; 40 (12): 1574-1579.
24. Greene ND, Copp AJ,. Inositol prevents folate-resistant neural tube defects in the mouse. Nat Med. 1997; 3 (1): 60-66.
25. Reece EA, Khandelwal M, Wu YK, Borenstein M,. Dietary intake of myo-inositol and neural tube defects in offspring of diabetic rats. Am J Obstet Gynecol. 1997; 176 (3): 536-539.
26. Cogram P, Tesh S, Tesh J, et al. D-chiro-inositol is more effective than myo-inositol in preventing folate-resistant mouse neural tube defects. Hum Reprod. 2002; 17 (9): 2451-2458.
27. Cavalli P, Copp AJ,. Inositol and folate resistant neural tube defects. J Med Genet. 2002; 39 (2): E5.02 Sep;17(9): 2451-2458.
28. Cavalli P, Tedoldi S, Riboli B,. Inositol supplementation in pregnancies at risk of apparently folate-resistant NTDs. Birth Defects Res A Clin Mol Teratol. 2008; 82 (7): 540-542.
29. Cavalli P, Tonni G, Grosso E, Poggiani C,. Effects of inositol supplementation in a cohort of mothers at risk of producing an NTD pregnancy. Birth Defects Res A Clin Mol Teratol. 2011; 91 (11): 962-965.
30. Corrado F, D'Anna R, Di Vieste G, et al. The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes. Diabet Med. 2011; 28 (8): 972-975.
31. D'Anna R, Di Benedetto V, Rizzo P, et al. Myo-inositol may prevent gestational diabetes in PCOS women. Gynecol Endocrinol. 2012; 28 (6): 440-442.
32. D'Anna R, Scilipoti A, Giordano D, et al. myo-Inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care. 2013; 36 (4): 854-857.
33. Matarrelli B, Vitacolonna E, D'Angelo M, et al. Effect of dietary myo-inositol supplementation in pregnancy on the incidence of maternal gestational diabetes mellitus and fetal outcomes: a randomized controlled trial. J Matern Fetal Neonatal Med. 2013; 26 (10): 967-972.
34. Gizzo S, Andrisani A, Esposito F, Oliva A, Zicchina C, Capuzzo D, Gangemi M, Nardelli GB,. Ovarian reserve test: an impartial means to resolve the mismatch between chronological and biological age in the assessment of female reproductive chances. Reprod Sci. 2014; 21 (5): 632-9.
35. Steegers-Theunissen RP, Twigt J, Pestinger V, Sinclair KD,. The periconceptional period, reproduction and long-term health of offspring: the importance of one-carbon metabolism. Hum Reprod Update. 2013; 19 (6): 640-655.
36. Leary C, Leese HJ, Sturmey RG,. Human embryos from overweight and obese women display phenotypic and metabolic abnormalities. Hum Reprod. 2015; 30 (1): 122-132.
37. Schulte MM, Tsai JH, Moley KH,. Obesity and PCOS: the effect of metabolic derangements on endometrial receptivity at the time of implantation. Reprod Sci. 2015; 22 (1): 6-14.
38. Rondanelli M, Perna S, Faliva M, Monteferrario F, Repaci E, Allieri F,. Focus on metabolic and nutritional correlates of polycystic ovary syndrome and update on nutritional management of these critical phenomena. Arch Gynecol Obstet. 2014; 290 (6): 1079-92;.
39. Qiao J, Feng HL,. Extra- and intra-ovarian factors in polycystic ovary syndrome: impact on oocyte maturation and embryo developmental competence. Hum Reprod Update. 2011; 17 (1): 17-33.
40. Nestler JE, Jakubowicz DJ, Reamer P, Gunn RD, Allan G,. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med. 1999; 340 (17): 1314-20.
41. Pizzo A, Laganà AS, Barbaro L,. Comparison between effects of myo-inositol and D-chiro-inositol on ovarian function and metabolic factors in women with PCOS. Gynecol Endocrinol. 2014; 30 (3): 205-208.
42. Copp AJ, Greene ND,. Genetics and development of neural tube defects. J Pathol. 2010; 220 (2): 217-230.
43. Groenen PM, Wevers RA, Janssen FS, Tuerlings JH, Merkus JM, Steegers-Theunissen RP,. Are myo-inositol, glucose and zinc concentrations in amniotic fluid of fetuses with spina bifida different from controls? Early Hum Dev. 2003; 71 (1): 1-8.
44. Dawson EB, Evans DR, Van Hook JW,. Amniotic fluid B12 and folate levels associated with neural tube defects. Am J Perinatol. 1998; 15 (9): 511-514.
45. Scioscia M, Vimercati A, Selvaggi LE, Rodeck CH, Rademacher TW,. Inositol phosphoglycan putative insulin mediator in human amniotic fluid. J Matern Fetal Neonatal Med. 2006; 19 (1): 9-12.
46. Groenen PM, Peer PG, Wevers RA, et al. Maternal myo-inositol, glucose, and zinc status is associated with the risk of offspring with spina bifida. Am J Obstet Gynecol. 2003; 189 (6): 1713-1719.
47. Scalera V, Natuzzi D, Prezioso G,. myo-inositol transport in rat intestinal brush border membrane vesicles, and its inhibition by D-glucose. Biochim Biophys Acta. 1991; 1062 (2): 187-192.
48. Genazzani AD, Prati A, Santagni S, et al. Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients. Gynecol Endocrinol. 2012; 28 (12): 969-973.
49. Baptiste CG, Battista MC, Trottier A, Baillargeon JP,. Insulin and hyperandrogenism in women with polycystic ovary syndrome. J Steroid BiochemMolBiol. 2010; 122 (1-3): 42-52.
50. Wilmot EG, Mansell P,. Diabetes and pregnancy. Clin Med. 2014; 14 (6): 677-680.
51. Kaul P, Savu A, Nerenberg KA, et al. Impact of gestational diabetes mellitus and high maternal weight on the development of diabetes, hypertension and cardiovascular disease: a population-level analysis. Diabet Med. 2015; 32 (2): 164-173.
52. International Association of Diabetes and Pregnancy Study Groups Consensus Panel, Metzger BE, Gabbe SG, Persson B, et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care. 2010; 33 (3): 676-682.
53. D'Anna R Sr, Santamaria A, Corrado F, Benedetto AD, Petrella E, Facchinetti F,. [11-OR]: Myo-inositol in the prevention of gestational diabetes and its complications. Pregnancy Hypertens. 2015; 5 (1): 6.
54. Patrelli TS, Dall'asta A, Gizzo S, et al. Calcium supplementation and prevention of preeclampsia: a meta-analysis. J Matern Fetal Neonatal Med. 2012; 25 (12): 2570-2574.
55. Gizzo S, Noventa M, Di Gangi S, et al. Could molecular assessment of calcium metabolism be a useful tool to early screen patients at risk for pre-eclampsia complicated pregnancy? Proposal and rationale. Clin Chem Lab Med. 2015; 53 (7): 975-979.
56. Vitagliano A, Quaranta M, Noventa M, Gizzo S,. "Empiric" inositol supplementation in normal-weight non insulin resistant women with polycystic ovarian disease: from the absence of benefit to the potential adverse effects. Arch Gynecol Obstet. 2015; 291 (5): 955-957.